

# Anastasia Stukan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2729410/publications.pdf>

Version: 2024-02-01

12  
papers

9  
citations

2682572

2  
h-index

2550090

3  
g-index

12  
all docs

12  
docs citations

12  
times ranked

3  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human papillomavirus-associated oropharyngeal carcinoma: trends in epidemiology and methods for detecting the virus in tumors. <i>Opuholi Golovy I Sei</i> , 2018, 8, 77-83.	0.4	3
2	Germinal & BRCA-mutation significance in the tumor microenvironment formation Efficacy of PARP inhibition in late-line therapy of metastatic castration-resistant prostate cancer. <i>Onkourologiya</i> , 2021, 17, 85-94.	0.3	2
3	Liquid biopsy: the current state of the issue. <i>Innovative Medicine of Kuban</i> , 2021, , 57-63.	0.2	1
4	Clinical significance of P16-positive status and high index of proliferative activity in patients with oropharyngeal squamous cell carcinoma. <i>Siberian Journal of Oncology</i> , 2020, 19, 41-48.	0.3	1
5	PATHOGENETIC RATIONALE FOR THE USE OF CELL THERAPY IN LUNG INJURY ASSOCIATED WITH SARS-COV-2. <i>Innovative Medicine of Kuban</i> , 2020, , 69-78.	0.2	1
6	Dynamic changes in the tumor microenvironment under the effect of estradiol as a diagnostic tool and target for targeted cancer therapy. <i>Bulletin of Siberian Medicine</i> , 2022, 21, 171-182.	0.3	1
7	Mechanisms of metastasis and development of resistance to therapy in breast cancer. A clinical case of the effectiveness of ixabepilone in hormone-receptorpositive breast cancer with multidrug resistance. <i>Meditinskiy Sovet</i> , 2021, , 138-146.	0.5	0
8	Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors. <i>Meditinskiy Sovet</i> , 2021, , 84-93.	0.5	0
9	Molecular features evaluation of metastatic foci as the basis for metastatic breast cancer treatment personalization. Is there a place of CDK4/6-inhibitors in late-line therapy after chemotherapeutic regimens?. <i>Meditinskiy Sovet</i> , 2021, , 54-61.	0.5	0
10	Role of pre-metastatic niche in organ specificity of breast cancer metastasis. Influence on metastatic potential as a basis for CDK4/6-inhibition efficacy in early therapy of disseminated hormone-receptor-positive disease. <i>Meditinskiy Sovet</i> , 2021, , 25-34.	0.5	0
11	Evolution of the CDK4/6 inhibitor abemaciclib: from palliative to adjuvant therapy. Clinical experience with abemaciclib in patients with hormone-receptor-positive, HER2-negative breast cancer. <i>Meditinskiy Sovet</i> , 2022, , 40-48.	0.5	0
12	Induction of ovarian steroidogenesis as an additional potential risk factor for progression in premenopausal patients with hormone-receptor-positive breast cancer receiving tamoxifen as adjuvant therapy. <i>Meditinskiy Sovet</i> , 2022, , 131-138.	0.5	0